The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace

被引：17

作者：

Sollano, J. A. ^{[1
]}

Kirsch, J. M. ^{[2
]}

Bala, M. V. ^{[3
]}

Chambers, M. G. ^{[2
]}

Harpole, L. H. ^{[4
]}

机构：

[1] GlaxoSmithKline Inc, King Of Prussia, PA USA

[2] GlaxoSmithKline Inc, Stockley Pk, Middx, England

[3] GlaxoSmithKline Inc, Collegeville, PA USA

[4] GlaxoSmithKline Inc, Res Triangle Pk, NC USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 84卷 / 02期

关键词：

D O I：

10.1038/clpt.2008.117

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Although it is commonly believed that the innovation of new medicines is of paramount importance for improving the health and quality of life of patients, there is also a keen recognition regarding upward-spiraling costs of innovation, drug discovery, and drug development against a backdrop of dwindling successes in research and development (R&D) efforts. We propose a new model of valuation of pharmacotherapies that attempts to secure an adequate return on investment in innovation by ensuring optimal pricing and reimbursement.

引用

页码：263 / 266

页数：4

共 7 条

[1] Value based pricing for NHS drugs: an opportunity not to be missed? [J].

Claxton, Karl ;

Lindsay, Andrew Briggs ;

Buxton, Martin J. ;

Culyer, Anthony J. ;

McCabe, Christopher ;

Walker, Simon ;

Sculpher, Mark J. .

BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7638) :251-254

[2]

*CTR MED MED SERV, 2006, NAT HLTH CAR EXP DAT

[3]

Culyer Anthony, 2007, J Health Serv Res Policy, V12, P56, DOI 10.1258/135581907779497567

[4] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185

[5]

GILBERT J, 2003, BUSINESS MED REP, V21, P10

[6]

LAM MD, 2004, PHARMEXEC COM

[7]

LICHTENBERG F, 2005, INT J HEALTH CARE FI, V1, P47

← 1 →